Stay updated with breaking news from Per Plotnikof. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF), a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and...
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that Henriette Mersebach will take up the position as Executive Vice President,...
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Four leading experts in respiratory allergy spotlight the impact of respiratory allergy in children, in an ALK-sponsored symposium at the EAACI CongressThe...
27.06.2022 - ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): ALK initiates a Phase I clinical trial of its novel investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy. The trial marks the formal start of clinical ...